Alliqua (ALQA) Prelim. Q2 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Alliqua BioMedical, Inc. Announces Preliminary Second Quarter of Fiscal Year 2016 Revenue; Earnings Conference Call Scheduled for August 9th
July 7, 2016 7:20 AM EDTYARDLEY, Pa., July 07, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced preliminary second quarter of fiscal year 2016 revenue results and timing and details of the second quarter financial results conference call.
Second Quarter Preliminary Revenue Estimate:
While the Company has not finalized its full financial results for the six month period ending June 30, 2016, it expects second quarter total revenue of approximately $5.4 million, representing growth... More
